Chen W, Berke A, Chung W, et al. - In this retrospective analysis, researchers examined 63 patients (mean age 82 ± 8 years, 48% male) treated with the MitraClip for significant mitral regurgitation (MR) in order to find out the factors predictive of adverse clinical outcomes, with a special emphasis on acute changes in hemodynamics and cardiac function. A composite of cardiac mortality and readmission for heart failure defined a major adverse cardiac event. They observed the patients over an average duration of 380 days. Findings revealed an attenuation in LV end-diastolic volume and improvement in hemodynamics early after MitraClip therapy. An increased risk of mortality and heart failure was observed in relation to advanced age (≥ 85 years) and residual MR > 1+.